Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response

This publication has 12 references indexed in Scilit:

• Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation
  Blood, 2002
• Role of Nonmyeloablative Allogeneic Stem-Cell Transplantation After Failure of Autologous Transplantation in Patients With Lymphoproliferative Malignancies
  Journal of Clinical Oncology, 2002
• Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease
  Bone Marrow Transplantation, 2000
• Abundance of cyclin B1 regulates γ-radiation–induced apoptosis
  Blood, 2000
• Adoptive immunotherapy with donor lymphocyte infusionsafter allogeneic HPC transplantation
  Transfusion, 2000
• Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
  Journal of Clinical Oncology, 1997
• Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation.
  Journal of Clinical Oncology, 1996
• Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease.
  Journal of Clinical Oncology, 1996
• Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience.
  Journal of Clinical Oncology, 1993
• Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose
  Blood, 1993